PACB - Accelerate Diagnostics Reports Q1 Loss Misses Revenue Estimates | Benzinga
Accelerate Diagnostics (NASDAQ: AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of $0.62 per share when it actually produced a loss of $0.89, delivering a surprise of -43.55%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Accelerate Diagnostics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $2.92 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.63%. This compares to year-ago revenues of $2.81 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings ...